Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30041432 | 1.00 | PTGS2 (0.56) | PTGS2PTGS1KMT2ATDP1KIF11 | |
| SCHEMBL2642850 | 0.82 | PTGS2 (0.47) | PTGS2KIF11 | |
| SCHEMBL2329775 | 0.82 | PTGS2 (0.64) | PTGS2PTGS1KMT2A | |
| SCHEMBL3757908 | 0.82 | PTGS2 (0.54) | PTGS2KIF11 | |
| SCHEMBL31704457 | 0.82 | SMN1; SMN2 (0.55) | PTGS2PTGS1KIF11 | |
| SCHEMBL21330942 | 0.82 | KMT2A (0.46) | PTGS2PTGS1KMT2ATDP1KIF11 | |
| SCHEMBL24691352 | 0.80 | PTGS2 (0.46) | PTGS2KIF11 | |
| SCHEMBL12469250 | 0.80 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL585689 | 0.80 | PTGS2 (0.65) | PTGS2PTGS1KMT2A | |
| SCHEMBL355740 | 0.80 | ENPP2 (0.50) | PTGS2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945608-A1 | SYNTHESIS OF METHYLSULPHONYL BENZENE COMPOUNDS | Peakdale Molecular Limited (GB) | 2008-07-23 | — | — | EP | claimed |
| WO-2007054668-A1 | SYNTHESIS OF METHYLSULPHONYL BENZENE COMPOUNDS | PEAKDALE MOLECULAR LIMITED (GB) | 2007-05-18 | — | — | WO | claimed |
| WO-2022253335-A1 | SULFONYL-CONTAINING ARYL COMPOUND AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-20200277271-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-09-03 | — | — | US | disclosed |
| US-10308605-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| WO-2018144900-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2017101890-A1 | SPIROKETAL DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION | 上海艾力斯医药科技有限公司 | 2017-06-22 | — | — | WO | disclosed |
| EP-2114917-B1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA (FR) | 2016-06-30 | — | — | US | disclosed |
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA (FR) | 2016-06-30 | — | — | US | disclosed |
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA (FR) | 2016-06-30 | — | — | US | disclosed |
| EP-1765768-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| CN-1922159-A | Benzamide derivatives and their use as glucokinase activating agents | ASTRAZENECA AB (SE) | 2007-02-28 | — | — | CN | disclosed |
| EP-1734040-A1 | SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| EP-1718624-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006040529-A1 | BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006005909-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005080359-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINAE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005080359-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINAE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308605-B2 | Proton pump inhibitors | HRH2, HRH4, HRH1 | PTGS2 413/4885PTGS1 154/4885KMT2A 2262/4885 |
| US-20200277271-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | SUMO2, SUMO1, SUMO3 | PTGS2 1697/4885PTGS1 2331/4885KMT2A 2071/4885 |
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | HPD, HPGDS, EPX | PTGS2 99/4885PTGS1 89/4885KMT2A 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.